Table 4: Probabilities of patients developing haematological toxicities stratified by chemotherapy regimen.

Probability of developing
neutropeniafebrile neutropeniathrombocytopeniaanaemia

First-line treatments
 Doxorubicin/ifosfamide0.820.120.230.35
[23, 24, 26, 30][24, 26][17, 23, 24, 26, 30][23, 26, 30]
 Trabectedin0.330.000.000.03
[34][34][34][34]
Second-line treatments
 CYVADIC*∧0.520.190.170.16
 Docetaxel0.900.120.030.08
[36, 37][35, 37][3537][3537]
 Doxorubicin0.840.190.090.18*
[39][39][39]
 Doxorubicin/ifosfamide*0.520.190.170.18
 Gemcitabine0.180.070.180.11
[40, 41, 43, 47, 71][33, 40, 41, 43, 71][33, 4043, 46, 71][4043, 71]
 Gemcitabine/dacarbazine0.46 [49]0.19*0.12 [49]0.23 [49]
 Gemcitabine/docetaxel0.310.090.330.18
[52, 54][52, 54][40, 52, 54][52, 54]
 Gemcitabine/paclitaxel*0.520.190.170.16
 Gemcitabine/vinorelbine0.38 [56]0.08 [56]0.10 [56]0.05 [56]
 Ifosfamide0.820.390.130.12
[5760][58, 59][5760][5759]
 Ifosfamide/epirubicin*0.520.190.170.18
 Liposomal doxorubicin*0.070.020.000.35
 Trabectedin0.500.060.160.18
[19, 34, 61, 64, 65, 67][19, 34, 61, 65][19, 34, 61, 64, 65, 67][19, 34, 61, 65]
 Trofosfamide0.52*0.19*0.17*0.25 [70]
 Trofosfamide/etoposide*0.520.190.170.16

CYVADIC: cyclophosphamide, vincristine, adriamycin, and dacarbazine.
*Values were estimated.